Article
Oncology
Xinghao Ai, Yueyin Pan, Jianhua Shi, Nong Yang, Chunling Liu, Jianying Zhou, Xiaodong Zhang, Xiaorong Dong, Jianxing He, Xiaoling Li, Gongyan Chen, Xingya Li, Helong Zhang, Wangjun Liao, Yiping Zhang, Zhiyong Ma, Liyan Jiang, Jiuwei Cui, Chunhong Hu, Wei Wang, Cheng Huang, Jun Zhao, Cuimin Ding, Xiaohua Hu, Kai Wang, Beili Gao, Yong Song, Xiaoqing Liu, Jianping Xiong, Anwen Liu, Junling Li, Zhe Liu, Yinyin Li, Mengzhao Wang, Biao Zhang, Dan Zhang, Shun Lu
Summary: The study ZL-2306-005 did not meet its primary endpoints, but niraparib as maintenance therapy showed modest improvement in PFS for patients with platinum-responsive ES-SCLC, with acceptable tolerability and no new safety concerns.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Erika Hamilton, Evelyn L. Fleming, Jimmy Belotte, Erika K. Keeton, Ping Wang, Divya Gupta, Aine Clements, Heidi J. Gray, Gottfried E. Konecny, Richard G. Moore, Debra L. Richardson
Summary: This study evaluated the safety and efficacy of Niraparib + bevacizumab as a first-line maintenance therapy for newly diagnosed advanced ovarian cancer patients. The results showed promising PFS outcomes and the safety profile was consistent with the monotherapy of these drugs.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Juan F. Cueva, Isabel Palacio, Cristina Churruca, Ana Herrero, Beatriz Pardo, Manuel Constenla, Ana Santaballa, Luis Manso, Purificacin Estevez, Constanza Maximiano, Marta Legeren, Gloria Marquina, Ana de Juan, Maria Quindos, Luisa Sanchez, Arantzazu Barquin, Isaura Fernandez, Cristina Martin, Asuncin Juarez, Teresa Martin, Yolanda Garcia, Alfonso Yubero, Alejandro Gallego, Alejandro Martinez Bueno, Eva Guerra, Antonio Gonzalez-Martin
Summary: This retrospective observational study aimed to investigate the patient characteristics, effectiveness, and safety of niraparib in a real-world population. The results showed that niraparib maintenance therapy is well-tolerated and effective in patients with platinum-sensitive recurrent ovarian cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Antonio Gonzalez-Martin, Bhavana Pothuri, Ignace Vergote, Whitney Graybill, Domenica Lorusso, Colleen C. McCormick, Gilles Freyer, Floor Backes, Florian Heitz, Andres Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O'Cearbhaill, Izabela A. Malinowska, Luda Shtessel, Natalie Compton, Mansoor R. Mirza, Bradley J. Monk
Summary: This study reports the long-term efficacy and safety of the PRIMA/ENGOT-OV26/GOG-3012 trial. The results show that niraparib maintains clinically significant improvements in progression-free survival (PFS) in high-risk patients with newly diagnosed advanced ovarian cancer, regardless of HRD status. No new safety signals were identified.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Genetics & Heredity
Vanessa F. Bonazzi, Olga Kondrashova, Deborah Smith, Katia Nones, Asmerom T. Sengal, Robert Ju, Leisl M. Packer, Lambros T. Koufariotis, Stephen H. Kazakoff, Aimee L. Davidson, Priya Ramarao-Milne, Vanessa Lakis, Felicity Newell, Rebecca Rogers, Claire Davies, James Nicklin, Andrea Garrett, Naven Chetty, Lewis Perrin, John Pearson, Ann-Marie Patch, Nicola Waddell, Pamela M. Pollock
Summary: Endometrial cancer comprises four molecular subtypes with differing etiology, prognoses, and responses to chemotherapy. Patient-derived xenograft models have been successfully generated and showed sensitivity to PARP inhibitor in copy number high molecular subtype; however, deeper and more durable responses will likely require combination of PARPi with other agents.
Article
Oncology
Taigo Kato, Nobuaki Matsubara, Masaki Shiota, Masatoshi Eto, Takahiro Osawa, Takashige Abe, Nobuo Shinohara, Yota Yasumizu, Nobuyuki Tanaka, Mototsugu Oya, Koshiro Nishimoto, Takuji Hayashi, Masashi Nakayama, Takahiro Kojima, Kenjiro Namikawa, Takao Fujisawa, Susumu Okano, Eisuke Hida, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino, Norio Nonomura
Summary: This study aims to evaluate the efficacy and safety of PARPi plus ICI combination therapy in patients with HRR gene-mutated cancers. Through translational research, the study will reveal which patients would benefit from targeted combination therapy even after the failure of ICIs.
Article
Oncology
Marisa C. Liu, Joyce Sutedja, Krishnansu S. Tewari
Summary: Ovarian cancer is frequently diagnosed in late stages with ambiguous symptoms and a low survival rate. Niraparib, a PARP inhibitor, offers a new treatment modality for ovarian cancer patients through oral maintenance therapy regardless of biomarker status, with potential for new frontiers in treatment. New combination drug trials also present exciting avenues for treatment with promising outcomes.
EXPERT REVIEW OF ANTICANCER THERAPY
(2021)
Article
Oncology
Marianna Csaplar, Janos Szollosi, Stephen Gottschalk, Gyorgy Vereb, Arpad Szoor
Summary: Studies have shown that CAR T cell products with the highest proportion of effector cells and maintaining a good balance of CD4+/CD8+ cells are the most effective against solid tumors targeting HER2, both in vitro and in vivo. The differentiation status of CAR T cell products can affect their antitumor activity, with the most differentiated products showing greater target-specific cytolytic activity and antitumor efficacy. It is crucial to optimize CAR T cell production, as optimal product characteristics may vary depending on the targeted antigen and cancer type.
Article
Oncology
Misako Nagasaka, Danielle Brazel, Yasmine Baca, Joanne Xiu, Mohammed Najeeb Al-Hallak, Chul Kim, Jorge Nieva, Jeffrey J. Swensen, David Spetzler, Wolfgang Michael Korn, Mark A. Socinski, Luis E. Raez, Balazs Halmos, Sai-Hong Ignatius Ou
Summary: RET fusions are driver alterations found in various cancers, with non-small cell lung cancer (NSCLC) and well-differentiated thyroid cancer being the most common. This study analyzed clinical tumor samples using targeted RNA sequencing and whole transcriptome sequencing, and identified 378 RET+ solid malignancies in 15 different tumor types and carcinoma of unknown primary (CUP). NSCLC and thyroid cancer accounted for the majority of RET+ solid malignancies, while colorectal cancer and breast cancer constituted smaller proportions. The most common fusion partner was KIF5B, and different fusion variants dominated in different tumor types. RET+ colorectal cancer showed high median TMB and frequent MSI-H. Overall, RET fusions were found in multiple tumor types, and RET fusion positive colorectal cancer may represent a unique molecular subset of CRC.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Melanie A. Jones, Kirsten M. Timms, Shanell Hatcher, Elizabeth S. Cogan, Matthew S. Comeaux, Michael Perry, Brian Morris, Brad Swedlund, Cathy E. Elks, Pierre Lao-Sirieix, Simon Dearden, Coumaran Egile, Jessica S. Brown, Elizabeth A. Harrington, Darren Hodgson, Matt Stern, Thomas P. Slavin, Debora Mancini-DiNardo
Summary: This study examines the prevalence of pathogenic BRCA1/BRCA2 large rearrangements (LRs) in ovarian tumors and emphasizes the importance of accurately detecting them. The results show that over 6% of pathogenic variants in the analyzed tumors are LRs, primarily deletions, some of which occur within the same gene.
GENES CHROMOSOMES & CANCER
(2023)